'Disease X' Fears Boost K-Bio[K-Bio pulse] 작성일 05-22 31 목록 <div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="XGFsWVpXDl"> <p contents-hash="49b5784b5d64f8fbe688ae3ecf9e2aa50d5a725d61e5571ae14475b05c2d19c1" dmcf-pid="ZH3OYfUZIh" dmcf-ptype="general"> [Seungkwon Kim, Edaily Reporter] On May 20, South Korean bio and healthcare stocks rallied strongly driven by global Hantavirus fears and expectations for new infectious disease countermeasures. </p> <p contents-hash="06efc66a58cf2539d097ffcc3772687f50ac5fbcede3c27056cf9d06741d72b9" dmcf-pid="5X0IG4u5IC" dmcf-ptype="general">Eyegene led the surge, hitting near the daily upper limit after securing a government mRNA vaccine project. GC Medical Science also spiked over 28%, while surgical robot maker LivsMed gained 11% ahead of its new product launch.</p> <figure class="figure_frm origin_fig" contents-hash="ccf3b4281e869e4f88a46bb555fb599ee68506e7b8726e3a2120fdbab960a423" dmcf-pid="1ZpCH871EI" dmcf-ptype="figure"> <p class="link_figure"><img alt="Eyegene trend on May 20.(Image=Naver Finance)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202605/22/Edaily/20260522080508341xyeu.png" data-org-width="708" dmcf-mid="Y57VehcnET" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202605/22/Edaily/20260522080508341xyeu.png" width="658"></p> <figcaption class="txt_caption default_figure"> Eyegene trend on May 20.(Image=Naver Finance) </figcaption> </figure> <p contents-hash="4c27f6e6eec0d01dc65374aa5c3147b8551af47b08683f99efeff251b4a1b3b8" dmcf-pid="tFzv1xb0sO" dmcf-ptype="general"><strong>Eyegene, Tapped for Gov't Hantavirus mRNA Vaccine</strong></p> <p contents-hash="ea471b9f00f050c021f071f6aa13525f1d220d74b63439598b7d030c4bf13cb1" dmcf-pid="F3qTtMKprs" dmcf-ptype="general">Eyegene surged 29.8% to close at 2,235won. The jump followed its selection for two KDCA-backed national mRNA vaccine projects for Hantavirus and SFTS, securing 4 billionwon in state funding. Utilizing its proprietary, patent-free "Cap-less" mRNA platform, Eyegene aims to develop a universal Hantavirus vaccine. </p> <p contents-hash="ba8396cb711c8d2487837d9a87b6fd4e39e427b2fcf3c6d8aaf3265ea0bcec57" dmcf-pid="30ByFR9UOm" dmcf-ptype="general">Backed by its largest shareholder's GMP facility, the company is well positioned for immediate mass production and aims to achieve First in Class status globally amid rising pandemic threats.</p> <figure class="figure_frm origin_fig" contents-hash="28019ca15c2484c97bab0e389211b8d21df441e39d0a0b593749af68e5dd8891" dmcf-pid="0pbW3e2uEr" dmcf-ptype="figure"> <p class="link_figure"><img alt="GC Medical Science trend on May 20.(Image=Naver Finance)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202605/22/Edaily/20260522080509588gskz.png" data-org-width="703" dmcf-mid="G0OdAZhDEv" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202605/22/Edaily/20260522080509588gskz.png" width="658"></p> <figcaption class="txt_caption default_figure"> GC Medical Science trend on May 20.(Image=Naver Finance) </figcaption> </figure> <p contents-hash="747efc3701b4fa2fe0535785af0b26a1560d0f2a2a41c36dca2a69ce1f5520b1" dmcf-pid="pUKY0dV7Dw" dmcf-ptype="general"><strong>GC Medical Science, Surges on Infection Diagnostics Demand</strong></p> <p contents-hash="1c69385b29aa8c85010dd8527e77fa8ce0c4682d70b65371e7180de1fe883d75" dmcf-pid="Uu9GpJfzrD" dmcf-ptype="general">GC Medical Science rocketed 28.2% to 6,230won. As a subsidiary of the GC Green Cross Group which commercialized the world's first Hantavirus vaccine GC Medical Science benefited from a sector wide rally fueled by global "Disease X" and Hantavirus fears. </p> <p contents-hash="b99ed26c26aded963058c7a5ba480d9c150fd3f822ba7bfcf9c0f15f318d8d8c" dmcf-pid="u72HUi4qIE" dmcf-ptype="general">Although it does not directly produce a specific Hantavirus test kit, investors heavily priced in the group's strong bio security brand power and anticipated growth in broader diagnostic demands.</p> <figure class="figure_frm origin_fig" contents-hash="6686e4c28ef67ae9b8860882bec1308bb5af281eb8ac0672220c3a4d611e5dcd" dmcf-pid="7zVXun8BDk" dmcf-ptype="figure"> <p class="link_figure"><img alt="LivsMed trend on May 20.(Image=Naver Finance)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202605/22/Edaily/20260522080510800ckdb.png" data-org-width="708" dmcf-mid="HuHkhq5TES" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202605/22/Edaily/20260522080510800ckdb.png" width="658"></p> <figcaption class="txt_caption default_figure"> LivsMed trend on May 20.(Image=Naver Finance) </figcaption> </figure> <p contents-hash="a993f1c0b2171ab48dc01c14f94c91ef525da0a2f1b7936ebe85c2dffbbb5e5d" dmcf-pid="zqfZ7L6bEc" dmcf-ptype="general"><strong>LivsMed, 1000 IP Milestone and Upcoming 'STARK' Launch</strong></p> <p contents-hash="3e746e1dae117b714b6d0b48e7fa138f2342f1aaccdbf1601e233e644c65c8b7" dmcf-pid="qAmRNHIkEA" dmcf-ptype="general">LivsMed climbed 11.3% to 63,000won, driven by its announcement of surpassing 1,000 intellectual property (IP) cases. With an average remaining patent life of 17 years, the company has secured a robust barrier for its core multi joint technologies. </p> <p contents-hash="57de085ec5a358cec93bf523bfc4ed1800b7c06bf633530bdbd42ce053ac3233" dmcf-pid="BcsejXCEwj" dmcf-ptype="general">Investor anticipation is also building for the May 26 unveiling of its next-generation laparoscopic surgical robot "STARK™" which is poised to drive mid to long term growth and offset recent seasonal earnings volatility.</p> <p contents-hash="47df66c0d89529e7a596a50d37175b0282efdb7f0deeb664d5915aea37a230aa" dmcf-pid="bkOdAZhDON" dmcf-ptype="general">김승권 (peace@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p> 관련자료 이전 아이진, 한타바이러스 백신 과제 선정에 '上'…녹십자MS·리브스메드 '들썩'[바이... 05-22 다음 55회 전국소년체전 23일 부산서 개막…40개 종목 1만8000여명 참가 05-22 댓글 0 등록된 댓글이 없습니다. 로그인한 회원만 댓글 등록이 가능합니다.
